Clinical trial
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line…
NCT00202774 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Other · Completed
Key facts
| NCT number | NCT00202774 |
|---|---|
| Title | Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer |
| Official title | Phase III, Multicenter, Ramdomised, Open-label, Study to Evaluate the Safety and Efficacy of Combination Therapy With XELOX vs. Oxaliplatin and 5-FU CI as First Line Treatment in Advanced or Metastatic Colorectal Cancer |
| Lead sponsor | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | (capecitabine, oxaliplatin, 5-fluorouracil) |
| Enrollment | 348 |
| Start date | Apr 1, 2002 |
| Primary completion | Aug 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 12, 2023 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: